Diamond Hill Capital Management LLC Investment Advisor Buys New Shares in Solventum Corporation $SOLV

Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in shares of Solventum Corporation (NYSE:SOLV) in the 2nd quarter, Holdings Channel reports. The institutional investor purchased 1,945,121 shares of the company’s stock, valued at approximately $150,066,000. Solventum accounts for 1.2% of Diamond Hill Capital Management LLC Investment Advisor’s investment portfolio, making the stock its 28th largest holding.

Other hedge funds and other institutional investors have also bought and sold shares of the company. US Bancorp DE grew its stake in shares of Solventum by 4.6% during the 4th quarter. US Bancorp DE now owns 444,540 shares of the company’s stock valued at $35,225,000 after acquiring an additional 19,400 shares during the period. Davis Selected Advisers raised its stake in Solventum by 12.7% during the 4th quarter. Davis Selected Advisers now owns 6,220,072 shares of the company’s stock worth $492,880,000 after acquiring an additional 702,461 shares during the period. SG Americas Securities LLC raised its stake in Solventum by 38.4% during the 1st quarter. SG Americas Securities LLC now owns 129,663 shares of the company’s stock worth $8,467,000 after acquiring an additional 35,982 shares during the period. Ruffer LLP lifted its holdings in Solventum by 196.1% during the fourth quarter. Ruffer LLP now owns 614,558 shares of the company’s stock valued at $48,773,000 after purchasing an additional 407,001 shares in the last quarter. Finally, Bank of America Corp DE lifted its holdings in Solventum by 0.6% during the first quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock valued at $93,561,000 after purchasing an additional 9,083 shares in the last quarter.

Analysts Set New Price Targets

A number of equities analysts have weighed in on SOLV shares. Mizuho set a $113.00 price objective on shares of Solventum in a research note on Thursday, August 6th. BTIG Research raised their price objective on shares of Solventum from $91.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Stifel Nicolaus upped their target price on shares of Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wells Fargo & Company cut their price target on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th. Finally, Piper Sandler raised their price target on Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $91.64.

Solventum Stock Down 0.1%

Shares of SOLV stock opened at $88.53 on Monday. The stock has a market cap of $15.07 billion, a P/E ratio of 10.82, a PEG ratio of 1.14 and a beta of 0.60. Solventum Corporation has a 52 week low of $62.38 and a 52 week high of $90.00. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The company’s fifty day simple moving average is $80.11 and its two-hundred day simple moving average is $74.64.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The firm had revenue of $2.21 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same quarter last year, the business posted $1.69 earnings per share. The business’s quarterly revenue was up 2.2% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Analysts predict that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.